VI Partners’ portfolio company Inositec AG has been acquired by Vifor Pharma. Swiss-based Inositec is developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders. Its lead vascular calcification inhibitor, INS-3001, is being developed to treat indications of high unmet medical need and has obtained approval for its phase-I trial, with the first healthy volunteer to be dosed on November 30, 2021. If successful, the plan is to initiate two phase-II programs in 2023, one in non-dialysis CKD patients suffering from PAD, and a separate trial in patients suffering from AVS, a serious condition whereby the aortic valves calcify to the extent that surgical intervention is the only available option..

VI Partners had invested in Inositec at its foundation in 2016 and played an important active role in the company’s development.

Simultaneously with the acquisition of Inositec, Vifor also announced the purchase of Sanifit Therapeutics. See full press release here.